NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

Phase 2

Recruiting

Conditions: Recurrent Prostate Cancer
Prostate Cancer
PET Positive

Interventions: Drug: Enzalutamide
Drug: PDS01ADC

First Posted Date: 2023-10-24

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT06096870

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Phase 3

Recruiting

Conditions: Stage IIIB Lung Cancer AJCC v8
Stage IIIC Lung Cancer AJCC v8
Advanced Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8

Interventions: Procedure: Computed Tomography
Drug: Carboplatin
Procedure: Magnetic Resonance Imaging
Biological: Pembrolizumab
Procedure: Positron Emission Tomography
Drug: Nab-paclitaxel
Other: Questionnaire Administration
Drug: Paclitaxel
Drug: Pemetrexed

First Posted Date: 2023-10-24

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 304

Registration Number: NCT06096844

Locations: 🇺🇸
Highlands Oncology Group - Rogers, Rogers, Arkansas, United States
🇺🇸
Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States
🇺🇸
Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States

and more 284 locations

VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B

Phase 2

Recruiting

Conditions: Chronic Hepatitis B

Interventions: Drug: VIR-2218 and peginterferon alfa-2a

First Posted Date: 2023-10-23

Last Posted Date: 2025-05-18

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 50

Registration Number: NCT06092333

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Phase 1

Recruiting

Conditions: Familial Platelet Disorder With Predisposition to Myeloid Malignancies
Inherited Bone Marrow Failure Syndrome

Interventions: Drug: imatinib
Device: TruSight Oncology

First Posted Date: 2023-10-19

Last Posted Date: 2025-03-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 78

Registration Number: NCT06090669

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Phase 1

Recruiting

Conditions: Metastatic Alveolar Soft Part Sarcoma
Locally Advanced Alveolar Soft Part Sarcoma
Locally Advanced Hepatocellular Carcinoma
Locally Advanced Non Small Cell Lung Cancer
Locally Advanced Melanoma
Metastatic Hepatocellular Carcinoma
Locally Advanced Small Cell Lung Cancer
Metastatic Non Small Cell Lung Cancer
Metastatic Small Cell Lung Cancer
Metastatic Melanoma

Interventions: Drug: Atezolizumab

First Posted Date: 2023-10-04

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT06066138

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Phase 2

Recruiting

Conditions: Stage IV Nasopharyngeal Carcinoma AJCC v8
Stage II Nasopharyngeal Carcinoma AJCC v8
Stage III Nasopharyngeal Carcinoma AJCC v8

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Chest Radiography
Drug: Cisplatin
Procedure: Computed Tomography
Procedure: Echocardiography Test
Other: Electronic Health Record Review
Other: Fluciclovine F18
Drug: Gemcitabine
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
Biological: Nivolumab
Procedure: Positron Emission Tomography
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Radiation Therapy
Procedure: X-Ray Imaging

First Posted Date: 2023-10-03

Last Posted Date: 2025-05-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT06064097

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
Kaiser Permanente Downey Medical Center, Downey, California, United States

and more 50 locations

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Phase 3

Recruiting

Conditions: Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
HER2-Negative Breast Carcinoma
Hormone Receptor-Positive Breast Carcinoma

Interventions: Other: Genetic Testing
Procedure: Biospecimen Collection
Drug: Cyclophosphamide
Drug: Doxorubicin
Procedure: Mammography
Biological: Durvalumab
Drug: Paclitaxel
Other: Quality-of-Life Assessment

First Posted Date: 2023-09-28

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3680

Registration Number: NCT06058377

Locations: 🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸
Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States

and more 460 locations

Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)

Phase 2

Recruiting

Conditions: KSHV Inflammatory Cytokine Syndrome (KICS)
Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease

Interventions: Drug: Pacritinib

First Posted Date: 2023-09-25

Last Posted Date: 2025-03-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 65

Registration Number: NCT06052618

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery

Phase 2

Suspended

Conditions: Resectable Intrahepatic Cholangiocarcinoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Drug: Cisplatin
Procedure: Computed Tomography
Biological: Durvalumab
Drug: Gemcitabine
Procedure: Magnetic Resonance Imaging
Procedure: Resection

First Posted Date: 2023-09-22

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT06050252

Locations: 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States

and more 54 locations

Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate

Not Applicable

Recruiting

Conditions: Obesity
Overweight

Interventions: Other: Standard Diet
Other: Ketogenic Diet
Dietary Supplement: Placebo
Dietary Supplement: Nicotinamide Riboside

First Posted Date: 2023-09-21

Last Posted Date: 2025-05-21

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 100

Registration Number: NCT06044935

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Home Terms & Conditions Privacy Policy